What happens after?

Last week we noted that the insulin companies were about to come under attack over the high cost of insulin issue. Well the assault began yesterday with Congressional hearings. Per a report posted on FirstWord Pharma;

“Two US House Democrats sent letters to Eli Lilly, Novo Nordisk and Sanofi seeking information on why the cost of insulin has skyrocketed in recent years. Frank Pallone, chairman of the Energy and Commerce Committee, and Diana DeGette, chair of the Oversight and Investigations Subcommittee, also asked the companies to disclose net profits for their insulin products for the last 10 years.”

These hearings . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.